Across TCGA pan-cancer cohorts, MEIKIN Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MEIKIN data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher MEIKIN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEIKIN expression acts as an unfavorable survival marker.
ESCA are the cancer types where MEIKIN Mutation most reproducibly stratifies survival.